SKSimon Ulvenes Kverneng

Simon Ulvenes Kverneng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Ulvenes Kverneng has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Wavelet-Based Tremor Quantification From Wrist-Worn Sensor Data in Home-Dwelling People With Parkinson’s Disease

    by Haakon Reithe, Monica Patrascu, Juan C. Torrado, Elise Førsund, Bettina S. Husebo, Simon U. Kverneng, Erika Sheard, Charalampos Tzoulis, Brice Marty

    Objective: Tremor symptoms in Parkinson’s disease (PD) are challenging to assess due to low resolution and subjectivity from standard clinical scales. To address this, wearable devices have been used, but algorithms have been relying on controlled or limited activity conditions. Our objective is to create a context-independent metric quantifying tremor in free-living conditions to bridge the gap between biomedical engineering and the PD field. Methods and procedures: We designed an algorithm which computes a tremor index (TI) from accelerometer data, collected via the Empatica E4 worn on the wrist by home dwelling people with PD. For validation, we use a within-participant design, comparing the TIs of the most and least tremor-affected hand. We included seven participants with unilateral tremor, monitored for two weeks each. The algorithm is able to compute TIs for a set of frequencies identified in literature as associated with different tremor types (3–12 Hz), over adjustable sampling time windows. Results: We show that the most tremor-affected hand yields a higher TI than the other hand for frequency sets that are individual to each person, in particular around 5-6 Hz where rest tremor typically occurs. We find that we can disambiguate tremor across 3-12 Hz from general movement and resting states. The number of frequencies with inter-hand separation correlate with the MDS-UPDRS part III tremor items. Conclusion: The designed tremor quantification algorithm can quantify tremor symptoms over time for people with PD and can be used to identify the individualized frequency ranges where these movements happen, in free-living conditions. Clinical and translational impact: By utilizing pervasive, easy-to-use wrist-wearable devices equipped with accelerometers, the proposed index has the potential to change how clinicians and researchers track tremor symptoms in the daily lives of patients.


  • Open Access

    Deep-learning segmentation of the substantia nigra from multiparametric MRI: Application to Parkinson’s disease

    by Peder A.G. Lillebostad, Tormund H. Njølstad, Signe Hogstad, Frank Riemer, Simon U. Kverneng, Kjersti E. Stige, Martin Biermann, Mandar Jog, Sagar Buch, E. Mark Haacke, et al.

    Loss of dopaminergic neurons in the substantia nigra (SN) pars compacta (SNc) is a pathological hallmark of Parkinson’s disease (PD). This is accompanied by a reduction of the dopamine synthesis byproduct neuromelanin (NM), which can be detected in vivo with NM-sensitive MRI, showing potential as a biomarker of PD. This relies on delineating the NM-rich region, which is achieved by applying manual or automated methods. Currently, there is a lack of publicly available tools for this task, so we trained a deep neural network intended for publishing, while exploring the effects of incorporating multiparametric MRI for segmenting the NM hyperintensity of the SN. We obtained multiple MRI contrasts, including NM-sensitive magnetization transfer contrast from 109 individuals (87 PD, 22 healthy controls) comprising a Norwegian and a Canadian cohort. The method was further evaluated on 209 MRIs from the Parkinson’s Progressive Markers Initiative (PPMI). We observed that models trained naively on images from a single site tended to perform very poorly when exposed to similar data from different sites, emphasizing the importance of validating on out-of-distribution data. By applying aggressive data augmentation, we could largely attenuate the problem. We also observed a small additional regularizing effect from training the neural network on multiparametric MRIs. Volume and contrast-to-noise ratio (CNR) of the SN hyperintensity to the crus cerebri were used to distinguish patients from controls, with an area under the receiver operating characteristic (AUROC) of 0.863. CNR was found to be a better marker of disease status than volume, and we discuss a potential confusion in discerning the two measures. No contralateral association was observed between the severity of motor symptoms and volume or CNR.


  • Open Access

    Platelet mitochondrial complex I and IV activities are not reliable stratification biomarkers in Parkinson's disease

    by Simon Ulvenes Kverneng, Sepideh Mostafavi, Yana Mikhaleva, Gard Aasmund Skulstad Johanson, Haakon Berven, Katarina Lundervold, Geir Olve Skeie, Erika Sheard, Mona Søgnen, Solveig Af Geijerstam, et al.

    Background: Mitochondrial dysfunction, particularly complex I (CI) deficiency, is considered an integral feature of Parkinson's disease (PD). However, recent findings indicate that widespread neuronal CI deficiency in the brain is only present in a subpopulation of 20–30% of cases. This stratification may be relevant for selecting participants for clinical trials, emphasizing the need for clinically applicable biomarkers. We previously reported CI deficiency in skeletal muscle biopsies of a subpopulation of persons with PD (PwPs), suggesting potential for mitochondrial stratification using extra-neural tissues. Platelets are another tissue previously reported to exhibit mitochondrial respiratory defects in PD. However, studies have generally involved small sample sizes and reported variable results. Objective: To determine whether platelets exhibit impaired mitochondrial respiratory chain complex activity in PwPs, or in a subpopulation of PwPs. Methods: Using spectrophotometric activity assays, we assessed CI and complex IV (CIV) activities in platelet samples from 61 PwPs and 31 neurologically healthy controls from a well-characterized prospective cohort. The correlation between activities measured in platelets and skeletal muscle was also explored in 51 of the same individuals. Results: Platelet CI and CIV activities showed no difference between PwPs and controls at the group level, nor evidence of a subgroup with deficiency of either complex. There was no correlation between complex activities in platelet samples and skeletal muscle biopsies from the same individuals. Conclusions: Based on these results, we propose that platelet CI or CIV activities are not sensitive markers of mitochondrial dysfunction in PD.


  • Open Access

    Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease

    by Simon Ulvenes Kverneng, Kjersti Eline Stige, Haakon Berven, Sepideh Mostafavi, Katarina Lundervold, Michele Brischigliaro, Brage Brakedal, Geir Olve Skeie, Irene Hana Flønes, Lilah Toker, et al.

    Background: Widespread neuronal mitochondrial complex I (CI) deficiency was recently reported to be a characteristic in a subgroup of individuals with idiopathic Parkinson’s disease (PD). Here, we sought to determine whether a CI-deficient subgroup could be discerned using clinically accessible muscle biopsies. We further hypothesized that the inconsistency of previous findings of mitochondrial respiratory impairment in PD muscle may be due to interindividual variation, with respiratory deficiency only occurring in a subgroup of cases. Methods: Using a cross-sectional design, vastus lateralis needle biopsies were collected from 83 individuals with PD and 29 neurologically healthy controls and analyzed by immunohistochemistry for CI and complex IV (CIV), cytochrome c oxidase/succinate dehydrogenase (COX/SDH) histochemistry, and spectrophotometric activity assays of complexes I–IV. Mitochondrial DNA (mtDNA) copy number, deletions, and point variation were analyzed in single muscle fibers and bulk biopsy samples. Results: We show that PD muscle exhibits reduced CI activity at the group level, with 9% of cases falling below two standard deviations of the control group. In contrast, the activities of CII–CIV are not significantly different between the PD and control groups. No quantitative change of CI or CIV is detected, and the observed functional CI deficiency is not associated with mtDNA abnormalities. Conclusions: Our findings support the existence of a PD subpopulation characterized by CI pathology in skeletal muscle and suggest that stratification by extra-neural mitochondrial dysfunction may be informative for selecting individuals for clinical trials.


  • Open Access

    Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease

    by Simon Ulvenes Kverneng, Kjersti Eline Stige, Haakon Berven, Sepideh Mostafavi, Katarina Lundervold, Michele Brischigliaro, Brage Brakedal, Geir Olve Skeie, Irene Hana Flønes, Lilah Toker, et al.

    Widespread neuronal complex I (CI) deficiency was recently reported to be a characteristic in a subgroup of individuals with idiopathic Parkinson’s disease (PD). Here, we sought to determine whether a CI deficient subgroup could be discerned using clinically accessible muscle biopsy. Vastus lateralis needle biopsies were collected from 83 individuals with PD and 29 neurologically healthy controls and analyzed by immunohistochemistry for complexes I and IV, cytochrome c oxidase/succinate dehydrogenase (COX/SDH) histochemistry, and spectrophotometric activity assays of complexes I-IV. Mitochondrial DNA (mtDNA) copy number, deletions, and point variation were analyzed in single muscle fibers and bulk biopsy samples. PD muscle exhibited reduced CI activity at the group level, with 9% of cases falling below two standard deviations of the control group. This deficiency was not associated with mtDNA abnormalities. Our findings support the existence of a PD subpopulation characterized by CI pathology and suggest that stratification by extra-neural mitochondrial dysfunction may be informative for selecting individuals for clinical trials.

  • Open Access

    The STRAT-PARK cohort: A personalized initiative to stratify Parkinson’s disease

    by Kjersti Eline Stige, Simon Ulvenes Kverneng, Soumya Sharma, Geir-Olve Skeie, Erika Sheard, Mona Søgnen, Solveig Af Geijerstam, Therese Vetås, Anne Grete Wahlvåg, Haakon Berven, et al.